David Miles

14.7k citations
94 papers · 8.4k · 4 hit papers · h-index 37

Impact in

Papers in

    • HER2/EGFR in Cancer Research 53
    • Cancer Treatment and Pharmacology 29
    • Peptidase Inhibition and Analysis 11
    • Cancer Immunotherapy and Biomarkers 10
    • Advanced Breast Cancer Therapies 14

David Miles

90 papers receiving 8.2k citations

David Miles's Hit Papers

Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial 2017 · 465 citations
4650+5+10Years since publication50010001.5k2.0k2.5k

Peers

David Miles
Comparison fields: 5 of 129
  • Oncology 6.0k
  • Radiology, Nuclear Medicine and Imaging 2.7k
  • Cancer Research 1.3k
  • Pulmonary and Respiratory Medicine 2.2k
  • Genetics 543
Replace Suzanne F. Jones with:
Suzanne F. Jones United States
Joan Albanell Spain
Federico Rojo Spain
William L. Dahut United States
Sarat Chandarlapaty United States
Stephen Chan United Kingdom
Ingrid A. Mayer United States
Glenn Liu United States
Roberto Bianco Italy
Amita Patnaik United States
David Miles relative to Suzanne F. Jones United States Suzanne F. Jones's profile →
Citations per field
00.5×3.3×
Suzanne F. Jones · 1×
Citations per year

Countries citing papers authored by David Miles

Since Specialization
Citations

This map shows the geographic impact of David Miles's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Miles with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Miles more than expected).

Fields of papers citing papers by David Miles

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Miles. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Miles. The network helps show where David Miles may publish in the future.

Co-authors

The 25 scholars most cited alongside David Miles, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David Miles Line = papers co-authored together David Miles links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 94 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Hit paper breakdown →
20122665
2
Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
Hit paper breakdown →
2010700
3
Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial
Hit paper breakdown →
2017465
4
Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy
Hit paper breakdown →
2010456
5 1999399
6 2014286
7 1998244
8 2011208
9 1970205
10 2010187
11 2014175
12 1999170
13 2002128
14 2010111
15 2006110
16 1994108
17 2013106
18 201692
19 201390
20 201686

About David Miles

David Miles is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging, Cancer Research and Molecular Biology, having authored 94 papers that have together received 8.4k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (53 papers), Cancer Treatment and Pharmacology (29 papers), Monoclonal and Polyclonal Antibodies Research (27 papers), Breast Cancer Treatment Studies (17 papers), Advanced Breast Cancer Therapies (14 papers), Peptidase Inhibition and Analysis (11 papers), Cancer Immunotherapy and Biomarkers (10 papers) and Immunotherapy and Immune Responses (10 papers). The work is most often cited by research in Oncology (6.0k citations), Radiology, Nuclear Medicine and Imaging (2.7k citations), Cancer Research (1.3k citations), Pulmonary and Respiratory Medicine (2.2k citations) and Genetics (543 citations). David Miles has collaborated with scholars based in United Kingdom, United States and Switzerland. Frequent co-authors include Luca Gianni, Véronique Dièras, José Baselga, Manfred Welslau, Ian E. Krop, Mark D. Pegram, Ellie Guardino, Sunil Verma, Kim T. Blackwell and Fang Ting Liang. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Cancer Research, British Journal of Cancer and Breast Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact